Urinary Lipid Peroxidation Byproducts: Are They Relevant for Predicting Neonatal Morbidity in Preterm Infants?

Fecha de publicación: 10/07/2015

Autores de IIS La Fe

Julia Kuligowski

Autor
Marta Aguar Carrascosa

Autor
Isabel Lliso Escudero

Autor
María Isabel Torres Cuevas

Autor
Justo Javier Escobar Cubiella

Autor
Guillermo Quintas Soriano

Autor
María De Brugada Montaner

Autor
Ángel Sánchez Illana

Autor
Máximo Vento Torres

Autor

Participantes ajenos a IIS La Fe

Rook D
van Goudoever JB

Grupos

Perinatología

Leader

Máximo Vento Torres

Abstract

Preterm infants have an immature antioxidant system; however, they frequently require supplemental oxygen. Oxygen-free radicals cause both pulmonary and systemic inflammation, and they are associated with increased morbidity and mortality. Consequently, screening of metabolite profiles representing the amount of lipid peroxidation is considered of great relevance for the evaluation of in vivo oxidative stress and derived inflammation and damage. Ranges for total relative contents of isoprostanes (IsoPs), isofurans (IsoFs), neuroprostanes (NeuroPs), and neurofurans (NeuroFs) within targeted SpO(2) ranges were determined in urine samples of 254 preterm infants <32 weeks of gestation within the frame of two randomized, controlled, and blinded clinical trials employing ultra-performance liquid chromatography-tandem mass spectrometry. A total of 536 serial urine samples collected during the first 4 weeks after birth in recruited infants who did not develop free radical associated conditions were analyzed. A reference range for lipid peroxidation byproducts, including isoprostanes, isofurans, neuroprostanes, and neurofurans, was calculated and possible correlations with neonatal conditions were investigated. Urinary elimination of isofurans in the first 4 days after birth correlated with later development of bronchopulmonary dysplasia. Our observations lead to the hypothesis that early urinary determination of lipid peroxidation byproducts, especially isofurans, is relevant to predict development of chronic lung conditions. Antioxid. Redox Signal. 23, 178-184.

Datos de la publicación

ISSN/ISSNe:: 1523-0864, 1557-7716
Tipo:: Article
Páginas:: 178-184
DOI:: 10.1089/ars.2015.6262
Factor de Impacto:: 3,066 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Kuligowski J:: Instituto de Investigación. 1 Neonatal Research Group, Health Research Institute La Fe , Valencia, Spain
Aguar M:: 2 Division of Neonatology, University and Polytechnic Hospital La Fe , Valencia, Spain
Lliso I:: Instituto de Investigación. 1 Neonatal Research Group, Health Research Institute La Fe , Valencia, Spain
Torres-Cuevas I:: Instituto de Investigación. 1 Neonatal Research Group, Health Research Institute La Fe , Valencia, Spain
Escobar J:: Instituto de Investigación. 1 Neonatal Research Group, Health Research Institute La Fe , Valencia, Spain
Quintás G:: 4 Department of Safety and Sustainability, Leitat Technological Center , Valencia, Spain
Brugada M:: 2 Division of Neonatology, University and Polytechnic Hospital La Fe , Valencia, Spain
Sánchez-Illana Á:: Instituto de Investigación. 1 Neonatal Research Group, Health Research Institute La Fe , Valencia, Spain
Vento M:: Instituto de Investigación. 1 Neonatal Research Group, Health Research Institute La Fe , Valencia, Spain

2 Division of Neonatology, University and Polytechnic Hospital La Fe , Valencia, Spain